<?xml version="1.0" encoding="utf-8"?>
<journal>
<title>International Journal of Radiation Research</title>
<title_fa>نشریه پرتو پژوه</title_fa>
<short_title>Int J Radiat Res</short_title>
<subject>Basic Sciences</subject>
<web_url>http://ijrr.com</web_url>
<journal_hbi_system_id>79</journal_hbi_system_id>
<journal_hbi_system_user>journal79</journal_hbi_system_user>
<journal_id_issn>2322-3243</journal_id_issn>
<journal_id_issn_online>2345-4229</journal_id_issn_online>
<journal_id_pii></journal_id_pii>
<journal_id_doi>10.61882/ijrr</journal_id_doi>
<journal_id_iranmedex></journal_id_iranmedex>
<journal_id_magiran></journal_id_magiran>
<journal_id_sid></journal_id_sid>
<journal_id_nlai></journal_id_nlai>
<journal_id_science></journal_id_science>
<language>en</language>
<pubdate>
	<type>jalali</type>
	<year>1401</year>
	<month>1</month>
	<day>1</day>
</pubdate>
<pubdate>
	<type>gregorian</type>
	<year>2022</year>
	<month>4</month>
	<day>1</day>
</pubdate>
<volume>20</volume>
<number>2</number>
<publish_type>online</publish_type>
<publish_edition>1</publish_edition>
<article_type>fulltext</article_type>
<articleset>
	<article>


	<language>en</language>
	<article_id_doi></article_id_doi>
	<title_fa></title_fa>
	<title>Dosimetric comparison of IMRT, VMAT and HYBRID treatment methods in radical radiation therapy of prostate cancer</title>
	<subject_fa>Radiation Biology</subject_fa>
	<subject>Radiation Biology</subject>
	<content_type_fa>تحقيق بديع</content_type_fa>
	<content_type>Original Research</content_type>
	<abstract_fa></abstract_fa>
	<abstract>&lt;div style=&quot;text-align: justify;&quot;&gt;&lt;span style=&quot;font-size:10pt&quot;&gt;&lt;span style=&quot;text-justify:inter-word&quot;&gt;&lt;span style=&quot;line-height:119%&quot;&gt;&lt;span style=&quot;font-family:Calibri&quot;&gt;&lt;span style=&quot;color:black&quot;&gt;&lt;span lang=&quot;en-US&quot; style=&quot;font-size:9.0pt&quot;&gt;&lt;span style=&quot;font-family:Calibri&quot;&gt;&lt;span style=&quot;color:#1f497d&quot;&gt;&lt;span style=&quot;font-style:italic&quot;&gt;&lt;span style=&quot;font-weight:bold&quot;&gt;&lt;span style=&quot;language:en-US&quot;&gt;Background&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span lang=&quot;en-US&quot; style=&quot;font-size:9.0pt&quot;&gt;&lt;span style=&quot;font-family:Calibri&quot;&gt;&lt;span style=&quot;color:#1f497d&quot;&gt;&lt;span style=&quot;font-weight:bold&quot;&gt;&lt;span style=&quot;language:en-US&quot;&gt;:&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt; &lt;span lang=&quot;en-US&quot; style=&quot;font-size:9.0pt&quot;&gt;&lt;span style=&quot;font-family:Calibri&quot;&gt;&lt;span style=&quot;language:en-US&quot;&gt;Modern treatment techniques such as Intensity-Modulated Radiotherapy(IMRT)or Volumetric-Modulated Arc Therapy(VMAT)&lt;/span&gt;&lt;/span&gt;&lt;/span&gt; &lt;span lang=&quot;en-US&quot; style=&quot;font-size:9.0pt&quot;&gt;&lt;span style=&quot;font-family:Calibri&quot;&gt;&lt;span style=&quot;language:en-US&quot;&gt;are standard in practice; it is possible to obtain much better dose distributions using HYBRID plans generated applying these techniques together. Thus patient&amp;rsquo;s quality of life improves.&amp;nbsp;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span lang=&quot;en-US&quot; style=&quot;color: black; font-family: Calibri; text-align: justify; font-size: 9pt;&quot;&gt;&lt;span style=&quot;color:#1f497d&quot;&gt;&lt;span style=&quot;font-style:italic&quot;&gt;&lt;span style=&quot;font-weight:bold&quot;&gt;Material and Methods&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span lang=&quot;en-US&quot; style=&quot;color: black; font-family: Calibri; text-align: justify; font-size: 9pt;&quot;&gt;&lt;span style=&quot;color:#1f497d&quot;&gt;&lt;span style=&quot;font-weight:bold&quot;&gt;:&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style=&quot;color: black; font-family: Calibri; font-size: 10pt; text-align: justify;&quot;&gt; &lt;/span&gt;&lt;span lang=&quot;en-US&quot; style=&quot;color: black; font-family: Calibri; text-align: justify; font-size: 9pt;&quot;&gt;In this study, treatment plan is generated for 10 prostate patients who underwent primary prostate radiotherapy with 7-field IMRT, double arc VMAT and HYBRID techniques. The prescribed treatment dose (78 &lt;/span&gt;&lt;span lang=&quot;en-US&quot; style=&quot;color: black; font-family: Calibri; text-align: justify; font-size: 9pt;&quot;&gt;Gray(&lt;/span&gt;&lt;span lang=&quot;en-US&quot; style=&quot;color: black; font-family: Calibri; text-align: justify; font-size: 9pt;&quot;&gt;Gy)) is defined as the isodose covering 95% of PTV.&lt;/span&gt;&lt;span style=&quot;color: black; font-family: Calibri; font-size: 10pt; text-align: justify;&quot;&gt; &lt;/span&gt;&lt;span lang=&quot;en-US&quot; style=&quot;color: black; font-family: Calibri; text-align: justify; font-size: 9pt;&quot;&gt;&lt;span style=&quot;color:#1f497d&quot;&gt;&lt;span style=&quot;font-style:italic&quot;&gt;&lt;span style=&quot;font-weight:bold&quot;&gt;Results&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span lang=&quot;en-US&quot; style=&quot;color: black; font-family: Calibri; text-align: justify; font-size: 9pt;&quot;&gt;&lt;span style=&quot;color:#1f497d&quot;&gt;&lt;span style=&quot;font-weight:bold&quot;&gt;:&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style=&quot;color: black; font-family: Calibri; font-size: 10pt; text-align: justify;&quot;&gt; &lt;/span&gt;&lt;span lang=&quot;en-US&quot; style=&quot;color: black; font-family: Calibri; text-align: justify; font-size: 9pt;&quot;&gt;The study results revealed better Planning Target Volume (PTV) dose coverage in the HYBRID plan than the other plans. At the same time, HYBRID plans were found to be significant in terms of heterogeneity index. It was observed that there was no statistically significant difference in terms of fit index. Bladder and rectum V&lt;/span&gt;&lt;span lang=&quot;en-US&quot; style=&quot;color: black; font-family: Calibri; text-align: justify; font-size: 5.9939pt;&quot;&gt;&lt;sub&gt;50&lt;/sub&gt;&lt;/span&gt;&lt;span lang=&quot;en-US&quot; style=&quot;color: black; font-family: Calibri; text-align: justify; font-size: 9pt;&quot;&gt; doses were lower in HYBRID plans than IMRT plans. The mean doses of the right and left femoral heads and the penile bulb V&lt;/span&gt;&lt;span lang=&quot;en-US&quot; style=&quot;color: black; font-family: Calibri; text-align: justify; font-size: 5.9939pt;&quot;&gt;&lt;sub&gt;90&lt;/sub&gt;&lt;/span&gt;&lt;span lang=&quot;en-US&quot; style=&quot;color: black; font-family: Calibri; text-align: justify; font-size: 9pt;&quot;&gt; in HYBRID plans were statistically significant compared to the IMRT and VMAT plans. VMAT plans had a lower rate of Monitor Unit (MU) in the MU assessment than IMRT plans; however, the MU rate obtained in the HYBRID plan was lowest compared to IMRT and VMAT plans. &lt;/span&gt;&lt;span lang=&quot;en-US&quot; style=&quot;color: black; font-family: Calibri; text-align: justify; font-size: 9pt;&quot;&gt;&lt;span style=&quot;color:#1f497d&quot;&gt;&lt;span style=&quot;font-style:italic&quot;&gt;&lt;span style=&quot;font-weight:bold&quot;&gt;Conclusion&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span lang=&quot;en-US&quot; style=&quot;color: black; font-family: Calibri; text-align: justify; font-size: 9pt;&quot;&gt;&lt;span style=&quot;color:#1f497d&quot;&gt;&lt;span style=&quot;font-weight:bold&quot;&gt;:&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style=&quot;color: black; font-family: Calibri; font-size: 10pt; text-align: justify;&quot;&gt; &lt;/span&gt;&lt;span lang=&quot;en-US&quot; style=&quot;color: black; font-family: Calibri; text-align: justify; font-size: 9pt;&quot;&gt;It was concluded that the HYBRID method is suitable for routine clinical use together with IMRT and VMAT plans since more optimum results were obtained in HYBRID plans, especially in critical organ doses.&lt;/span&gt;&lt;/div&gt;</abstract>
	<keyword_fa></keyword_fa>
	<keyword>Prostate cancer, IMRT, VMAT, HYBRID treatment planning,           critical organ doses.</keyword>
	<start_page>411</start_page>
	<end_page>416</end_page>
	<web_url>http://ijrr.com/browse.php?a_code=A-10-1-924&amp;slc_lang=en&amp;sid=1</web_url>


<author_list>
	<author>
	<first_name>N. </first_name>
	<middle_name></middle_name>
	<last_name>Ozturk</last_name>
	<suffix></suffix>
	<first_name_fa></first_name_fa>
	<middle_name_fa></middle_name_fa>
	<last_name_fa></last_name_fa>
	<suffix_fa></suffix_fa>
	<email>nural.ozturk@adu.edu.tr</email>
	<code>7900319475328460030433</code>
	<orcid>7900319475328460030433</orcid>
	<coreauthor>Yes
</coreauthor>
	<affiliation>Aydın Adnan Menderes University Medical Faculty, Department of Radiation Oncology,09010, Aydın, Turkey</affiliation>
	<affiliation_fa></affiliation_fa>
	 </author>


	<author>
	<first_name>N. </first_name>
	<middle_name></middle_name>
	<last_name>Ozbek</last_name>
	<suffix></suffix>
	<first_name_fa></first_name_fa>
	<middle_name_fa></middle_name_fa>
	<last_name_fa></last_name_fa>
	<suffix_fa></suffix_fa>
	<email></email>
	<code>7900319475328460030434</code>
	<orcid>7900319475328460030434</orcid>
	<coreauthor>No</coreauthor>
	<affiliation>Training and Research Hospital Radiation Oncology Clinic, Department of Physics, 34764 Ümraniye/İstanbul, Turkey</affiliation>
	<affiliation_fa></affiliation_fa>
	 </author>


	<author>
	<first_name>B. </first_name>
	<middle_name></middle_name>
	<last_name>Depboylu</last_name>
	<suffix></suffix>
	<first_name_fa></first_name_fa>
	<middle_name_fa></middle_name_fa>
	<last_name_fa></last_name_fa>
	<suffix_fa></suffix_fa>
	<email></email>
	<code>7900319475328460030435</code>
	<orcid>7900319475328460030435</orcid>
	<coreauthor>No</coreauthor>
	<affiliation>Aydın Adnan Menderes University Medical Faculty, Department of Radiation Oncology,09010, Aydın, Turkey</affiliation>
	<affiliation_fa></affiliation_fa>
	 </author>


</author_list>


	</article>
</articleset>
</journal>
